Apertor Pharmaceuticals is creating novel molecular glues for therapeutic applications in oncology. At Apertor we have developed a new class of therapeutics to address one of the toughest challenges in drug discovery — selective disruption of disease-causing protein-protein interactions (PPIs). Apertor’s Interceptors are designed to selectively disrupt protein complexes via proximity induction by recruiting an abundantly expressed protein naturally found in cancerous cells patient’s own proteins to safely and effectively block PPIs . Using our synthetic biology platform technology to invent and develop proprietary Interceptors, Apertor’s robust pipeline is unlocking new treatment possibilities for cancer patients. Apertor has identified its first development candidate targeting the mTORC1/4E-BP1 complex for the treatment of solid tumors in Q125, and has built a robust pipeline of additional programs addressing high-value oncology targets. Apertor raised $50M in Series A financing.